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Summary
Endometrial adenocarcinoma with signet-ring cells is an infrequent histological type of carcinoma that usually corresponds to a
metastasis of a primary carcinoma of another origin, mainly from the gastrointestinal tract or the breast. For this reason, in view of this
histological finding, it is essential to carry out a thorough evaluation including mammography, gastroscopy, colonoscopy and thoracoab-
dominopelvic CT. To date, only six cases of primary endometrial carcinoma with signet-ring cells have been reported in the English
literature. A 73-year-old patient was referred to the Gynecology Department with a 3-day history of postmenopausal bleeding. She was
diagnosed with primary endometrial adenocarcinoma with signet-ring cells. The anatomopathological special features of the surgical
specimen are presented, as well as the evolution of the patient, who remained asymptomatic and free of disease 28 months after surgery.
A review of the literature is performed, emphasizing the peculiarities of this rare histological subtype. Despite the fact that primary en-
dometrial carcinoma with signet-ring cells is an infrequent tumor, it must be considered in the differential diagnosis of malignant tumors
of aforesaid origin. It is essential to carry out a correct and an extensive investigative study as well as an immunohistochemical analysis
of the samples obtained for its confirmation diagnosis.
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Introduction
Endometrial adenocarcinoma with signet-ring cells is a
type of carcinoma that owes its peculiar appearance to the
presence of a large mucin-filled vacuole within its cells that
displaces the nucleus to the periphery [1]. When this infre-
quent histological subtype appears in the endometrium, it
usually corresponds to a metastasis of a primary carcinoma
of another origin, mainly from the gastrointestinal tract or
the breast [1].
The World Health Organization Classification of tumors
considers signet-ring cell carcinoma as a rare histological
variant of cervical carcinoma of the uterus, although it does
not include it among the histological variants of endometrial
carcinoma [2]. To date, only six cases of primary endome-
trial carcinoma with signet-ring cells have been published
in the English literature [1, 3-6].
The objective of this work is to present the case of a pa-
tient diagnosed with primary endometrial carcinoma with
signet-ring cells, performing a review of the literature on
this rare pathology.
The publication of this case report was approved by
Aragon Ethics Committee in Zaragoza, Spain, and com-
plied with the declaration of Helsinki for Human Research
of 1974 (last modified in 2000).
Case Report
A case of a 73-year-old patient, without toxic habits
(non-smoker, non-drinker of alcohol), with a body mass in-
dex of 32 kg/m2, hypertension and DM-2 undergoing treat-
ment with a surgical history of colpoperineoplasty in 2008
and endometrial polypectomy by hysteroscopy in 2011, is
presented. She was referred to the Gynecology Department
in November 2017 due to a postmenopausal bleeding of 3
days of evolution without other associated symptoms.
Gynecological examination revealed normal external
genitals, old blood remained in the vagina without active
bleeding, slightly prominent atrophic cervix, with normal
examination on bimanual palpation. The transvaginal ul-
trasound revealed a uterus with multiple myomas, with a
dominant 28mm intramural myoma on the left lateral face,
and a thickened and heterogeneous endometrium of 35 ×
30 × 17 mm without a visible subendometrial halo. An as-
piration biopsy was taken with a pathological diagnosis of
mucinous adenocarcinomawith signet-ring cells (Figure 1).
In the immunohistochemical study (IHC) it was found: Es-
trogenReceptors (ER) positive (90%), Progesterone Recep-
tors (PR) positive (80%), Vimentin positive, p16 negative,
Carcinoembryonic Antigen (CEA) positive, Cytokeratin 7
(CK7) positive, Cytokeratin 20 (CK20) negative, GATA3
negative and PAX8 positive. The immunohistochemical
overexpression of the hormonal receptors and vimentin, in
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Figure 1. — Endometrial mucosa with diffuse infiltration by signet-ring cells. (A) Endometrial mucosa with diffuse infiltration by signet-
ring cells. Normal endometrial gland is seen within the tumor. Hematoxylin-eosin (H&E) 10×. (B) Diffuse proliferation of signet-ring
cells: basophilic, mucinous cytoplasm and nucleus rejected to the periphery. H&E 20×.
Figure 2. — Immunohistochemical analysis. (A) Endometrial mucosa with diffuse infiltration by signet-ring cells. Cytokeratin 7 + 35,
7×. (B) Signet-ring cells: mucinous cytoplasm and nucleus pushed to the periphery. Cytokeratin 20-25, 4×. (C) Signet-ring cells PAX8
+ 35, 7×. (D) Signet-ring cells progesterone receptors (PR) + 32×.
addition to the negativity of p16, suggest endometrial origin
versus endocervical origin. Besides, negativity for GATA3
and CK20 seems to rule out a primary origin in the breast
and colon, respectively (Figure 2).
Magnetic resonance imaging (MRI) revealed an en-
dometrium occupied by a 40 × 28 × 35 mm lobulated,
poorly defined and heterogeneous mass, with post-contrast
















Table 1. — Published cases of Endometrial Adenocarcinoma with signet-ring cells: review of the literature.





Mooney et al. 1997 [3] 65 Asymptomatic Vimentin-/BRST-2-/CEA+ - HT+DA+BPL+ - Free of disease 6 monthsafter surgeryOmentectomía
Chebib et al. 2010
[4]
51 Trousseau Syndrome +
ascites + weight loss
CK7+/CK20-/p16-/CEA- IVB HT+DA+BPL QT (6 cycles with
Carboplatin + Taxol)
Death of metastasic disease
6 months after surgery
Boyd et al. 2010 [5] 46 Heavy menstrual
bleeding
ER+/CK7+/CEA+ - Subtotal HT - -
Boyd et al. 2010 [5] 59 Postmenopausal
bleeding
ER+/CK7+/CK20- - HT - -






IB HT+DA+BPL+PL - Free of disease 22 months
after surgery






IA HT+DA+BPL RT Free of disease 14 months
after surgery







QT (6 cycles with
Carboplatin + Taxol) + RT
Free of disease 28 months
after surgery
HT: Hysterectomy, DA: Double Anexectomy, BPL: bilateral pelvic lymphadenectomy, PL: Paraortic lymphadenectomy, QT: chemotherapy, RT: radiotherapy, CK7: Cy-
tokeratin 7, CK20: Cytokeratin 20, ER: Estrogen receptors, PR: progesterone receptors, CEA: carcinoembryonic antigen.
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quence. Besides, the mass invaded more than one-half of
the myometrium, predominantly on the anterior side. The
cervix appeared not to be invaded. Thoracoabdominopelvic
CT ruled out the existence of lymphadenopathy and neo-
plastic involvement at a distance. In the preoperative an-
alytical study tumor markers were requested, with CA-125
values of 15.77 U/ml and HE-4 of 152 pmol/L. The remain-
der of the evaluation, which included mammography, chest
X-ray, colonoscopy and gastroscopy, was normal.
In December 2017, complete staging surgery for en-
dometrial cancer was performed via abdominal, includ-
ing peritoneal lavages, simple total hysterectomy with bi-
lateral adnexectomy, pelvic and para-aortic lymphadenec-
tomy, and omentectomy. The patient postoperative course
was uneventful and she was discharged on the fifth day after
the intervention.
The definitive pathology diagnosis in the surgical spec-
imen, made by two expert gynecologic oncology pathol-
ogists, was FIGO IIIA undifferentiated endometrial ade-
nocarcinoma with signet-ring cells (pT3a (uterine serosa
involvement), pN0 (0/29)). In a multidisciplinary tumor
board, due to the definitive diagnosis and the advanced
FIGO stage of the tumor, it was decided to administer adju-
vant treatment with chemotherapy (carboplatin + paclitaxel
6 cycles), followed by adjuvant external radiotherapy (46
Gy divided in 23 doses) and brachytherapy to the vaginal
cuff, which ended in August 2018.
In April 2020, 28 months after surgery, the patient was
asymptomatic and without evidence of recurrence.
Discussion
Signet-ring cell adenocarcinoma is an infrequent pri-
mary tumor subtype in the endometrium. To date, only six
cases have been described in the literature, which are sum-
marized in Table 1.
The diagnosis of this type of adenocarcinoma is one of
exclusion, as in the presence of signet-ring cells in an en-
dometrial tumor, the first diagnosis to rule out is a metasta-
sis of a primary carcinoma of another origin, mainly from
the gastrointestinal tract or the breast. For this reason, it
is essential to carry out a thorough evaluation to include
mammography, gastroscopy, colonoscopy and thoracoab-
dominopelvic CT [1].
Likewise, in view of this histological finding, the IHC
analysis of the surgical specimen is essential and is quite
helpful to guide us towards the primary origin of the tumor.
In this sense, it has been described that primary endometrial
carcinoma is usually positive for cytokeratin 7 and nega-
tive for cytokeratin 20, while metastatic adenocarcinoma
of the colon is usually the opposite [1, 4, 5]. Furthermore,
negativity for GATA3, a marker not used in the previous
published cases, rules out the primary origin in the breast
because of its high sensitivity when there is a primary tu-
mor of the aforesaid origin [7]. Moreover, PAX8 is a novel
tumor marker whose positivity suggests a tumor origin in
the epithelium of the Müllerian ducts rather than a gastroin-
testinal or breast carcinoma [8]. In relation to CEA, a tumor
marker associated mainly with tumors of the gastrointesti-
nal tract, the cases published to date have not been consis-
tent in their results, since three cases were CEA negative [1,
4, 6], while three others were CEA positives [3, 5]. There-
fore, this marker has a limited value both to confirm or to
rule out a gastrointestinal origin of the primary tumor.
On the other hand, it is also important to make a differen-
tial diagnosis between an endometrial or cervical origin of
the tumor. The presence or absence of certain risk factors,
the findings of the physical examination and imaging tests
and the determination of the human papillomavirus (HPV)
status will help established the diagnosis, as well as the IHC
studies since the positivity of the hormonal receptors and vi-
mentin, and the negativity of p16, together with the absence
of HPV infection, suggest an endometrial origin of the le-
sion [1, 4, 5], while contrary results are associated with a
cervical origin, as published by Giordano et al. [9]Only
the case published by Pusiol et al. [6] had negative hor-
monal receptors and positive p16 as well as infection by
HPV genotype 11, despite the endometrium being its pri-
mary origin.
Furthermore, it is important to bear in mind that some-
times we can find signet-ring cells in the endometrium
whose origin is not neoplastic; this occurs occasionally dur-
ing the decidualization process of the endometrium [10] or
reactively after cervical cauterization [11].
Four of the published cases have appeared in post-
menopausal women [1, 3, 4, 5], in which the most described
symptom, as in the patient presented in this work, has been
bleeding [1, 5] In relation to the other two cases, one had
a late presentation with a clinical history of ascites, weight
loss, and bilateral deep vein thrombosis [4] while the other
turned up by chance in a screening cytology [3]. In contrast,
the two cases published in premenopausal women presented
with heavy menstrual bleeding of several months of evolu-
tion [5, 6].
Regarding the therapeutic management of this infre-
quent subtype of carcinoma, there is no standardized treat-
ment protocol and the cases published to date differ in the
schemes used. In relation to the surgical act, the majority
of cases include hysterectomy (HT) + double adnexectomy
(DA) + bilateral pelvic lymphadenectomy (BPL) in their
schemes [1, 3, 4, 6], while in the two cases byBoyd et al. [5]
only HT was performed. The FIGO stage and subsequent
disease-free survival of the patients are unknown. Only this
case and the one byPusiol et al. [6] include the performance
of a para-aortic lymphadenectomy. Moreover, an omentec-
tomy has only been carried out in two cases, this case and
the one by Mooney et al. [3]. Furthermore, in relation to
adjuvant treatment, only two of the cases published to date
received it. The patient reported by Chebib et al. [4] re-
ceived chemotherapy, while the patient reported presented
by Akkalp et al. [1] was treated with radiotherapy.
Despite this great discrepancy in the management
schemes used, these tumors tend to be considered as high-
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grade carcinomas and with a high risk of recurrence, so we
consider that the therapeutic attitude should be similar to
other high-risk endometrial carcinomas, performing com-
plete staging surgery followed by adjuvant treatment with
chemotherapy and radiotherapy [12, 13]. Only in this case
this scheme has been followed in its entirety, and due to the
good evolution the patient has had, being the one with the
longest isease-free interval to date (28 months), this scheme
could be considered the most appropriate therapeutic man-
agement option for this type of tumor.
Currently, it is very difficult to assess the long-term prog-
nosis of this kind of neoplasia because of the few cases de-
scribed in the literature to date and the short follow-up pe-
riod reported in most of them.
Conclusions
Despite the fact that primary endometrial carcinoma
with signet-ring cells is an infrequent tumor, it must be
taken into account in the differential diagnosis of malig-
nant tumors of the aforesaid origin. It is essential to carry
out a correct and extensive clinical evaluation, as well as an
immunohistochemical analysis of the samples obtained for
confirmation of the diagnosis.
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